Edition:
United Kingdom

Flex Pharma Inc (FLKS.OQ)

FLKS.OQ on NASDAQ Stock Exchange Global Market

0.34USD
8:59pm GMT
Change (% chg)

$-0.02 (-4.89%)
Prev Close
$0.36
Open
$0.36
Day's High
$0.37
Day's Low
$0.32
Volume
312,751
Avg. Vol
343,253
52-wk High
$8.95
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Christoph Westphal Reports Of 21.8 Percent Stake In Flex Pharma As Of Oct. 16
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Flex Pharma Inc ::CHRISTOPH WESTPHAL, M.D., PH.D. REPORTS STAKE OF 21.8 PERCENT IN FLEX PHARMA AS OF OCTOBER 16, 2018 - SEC FILING.  Full Article

Flex Pharma Reports Q2 LOSS PER SHARE $0.50
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Flex Pharma Inc ::FLEX PHARMA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.50.Q2 REVENUE $245,500.HAS STOPPED CLINICAL TRIALS IN MND AND CMT, WIND-DOWN OF THOSE STUDIES IS EXPECTED TO BE COMPLETED IN THE Q3 2018.  Full Article

Flex Pharma Q3 loss per share $0.54
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc ::Flex Pharma reports third quarter 2017 financial results.Q3 loss per share $0.54.Q3 revenue $414,000 versus I/B/E/S view $477,000.Q3 earnings per share view $-0.61 -- Thomson Reuters I/B/E/S.Flex Pharma Inc - ‍expects to have sufficient capital to fund operations into early 2019​.  Full Article

Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flex Pharma Inc :Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS.Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​.Flex Pharma Inc - ‍FLX-787 was generally well tolerated​.  Full Article

Flex Pharma initiates CMT phase 2 trial with FLX-787 in US
Monday, 16 Oct 2017 

Oct 16 (Reuters) - Flex Pharma Inc :Flex Pharma initiates CMT phase 2 trial with FLX-787 in US.Flex Pharma Inc - ‍ALS phase 2 trial currently underway​.Flex Pharma Inc - ‍expects to report topline results from this study in middle of 2018​.  Full Article